The Sustained-Release Dexamethasone Implant: Expanding Indications in Vitreoretinal Disease

References

• Herrero-Vanrell R, Cardillo JA, Kuppermann BD. Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clin Ophthalmol 2011;5:139–146
   PubMedGoogle Scholar
• Leopold IH. Nonsteroidal and steroidal anti-inflammatory agents. In: Surgical Pharmacology of the Eye. Sears ML, Tarkkanen A, eds., New York: Raven Press, 1985
   Google Scholar
• Stanbury RM, Graham EM. Systemic corticosteroid therapy-side effects and their management. Br J Ophthalmol 1998; 82(6):704–708
   PubMed Web of Science ®Google Scholar
• Weijtens O, Feron EJ, Schoemaker RC, et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am J Ophthalmol 1999; 128(2):192–197
   PubMed Web of Science ®Google Scholar
• Weijtens O, Schoemaker RC, Romijn FP, et al. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology 2002;109(10):1887–1891
   PubMed Web of Science ®Google Scholar
• Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110(4):681–686
   PubMed Web of Science ®Google Scholar
• Kwak HW, D’Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 1992;110(2):259–266
   PubMed Web of Science ®Google Scholar
• Chan A, Leung Loh-Shan, Blumenkranz MS. Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion. Clin Ophthalmol 2011;5:1043–1049
   Google Scholar
• Ferrini W, Ambresin A. Intravitreal dexamethasone implant for the treatment of macular edema after retinal vein occlusion in a clinical setting. Klin Monbl Augenheilkd 2013;230(4):423–426
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort Jr R, et al. Ozurdex GENEVA study group. Ophthalmology 2010;117(6):1134–46
   Google Scholar
• Haller JA, Bandello F, Belfort R Jr, et al. Ozurdex Geneva Study Group: Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve month study results. Ophthalmology 2011; 118(12):2453–2460
   PubMed Web of Science ®Google Scholar
• Loweder C, Belfort R Jr, Lightman S. Ozurdex HURON Study Group: Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011;129(5):545–553
   PubMed Web of Science ®Google Scholar
• Arcinue CA, Cerón OM, Foster CS. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther 2013;29(5):501–507
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125(3):309–317
   PubMed Web of Science ®Google Scholar
• Williams GA, Haller JA, Kuppermann BD, et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009;147(6):1048–1054
   PubMed Web of Science ®Google Scholar
• Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128(3):289–296
   PubMed Web of Science ®Google Scholar
• Dutra Medeiros M, Navarro R, Garcia-Arumi J, et al. Dexamethasone intravitreal implant for treatment of patients with recalcitrant macular edema resulting from Irvine-Gass syndrome. Invest Ophthalmol Vis Sci 2013;54(5):3320–3324
   PubMed Web of Science ®Google Scholar
• Brynskov T, Laugesen CS, Halborg J, et al. Longstanding refractory pseudophakic cystoid macular edema resolved using intravitreal 0.7mg dexamethasone implants. Clin Ophthalmol 2013;7:1171–1174
   PubMedGoogle Scholar
• Meye LM, Schonfeld CL. Cystoid macular edema after complicated cataract surgery resolved by an intravitreal dexamethasone 0.7-mg implant. Case Rep Ophthalmol 2011;2(3):319–322
   PubMedGoogle Scholar
• Callanan DG, Gupta S, Boyer DS. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013;120(9):1843--1851
   Google Scholar
• Boyer DS, Faber D, Gupta S. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized eyes. Retina 2011;31(5):915–923
   PubMed Web of Science ®Google Scholar
• Rishi P, Rishi E, Kuniyal L, Mathur G. Short-term results of intravitreal dexamethasone implant (Ozurdex) in treatment of recalcitrant diabetic macular edema: A case series. Oman J Ophthalmol 2012;5(2):79–82
   PubMedGoogle Scholar
• Sharma A, Madhusudhan RJ, Madahalli V, et al. Change in macular thickness in a case of refractory diabetic macular edema with dexamethasone intravitreal implant in comparison to intravitreal bevacizumab: A case report. Indian J Ophthalmol 2012;60(3):234–235
   PubMed Web of Science ®Google Scholar
• Zucchiatti I, Lattanzio R, Querques G, et al. Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthalmologica 2012;228(2):117–122
   PubMed Web of Science ®Google Scholar
• Cetin EN, Scanlon C, Akduman L. Outcomes of combined treatment with Ozurdex implant for macular edema in branch retinal vein occlusion. Association for Research in Vision and Ophthalmology, May 6, 2012, Fort Lauderdale, FL, USA
   Google Scholar
• Singer MA, Bell DJ, Woods P, et al. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion. Retina 2012;32(7):1289–1294
   PubMed Web of Science ®Google Scholar
• Mayer WJ, Remy M, Wolf A, et al. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema. Ophthalmologica 2012;228(2):110–116
   PubMed Web of Science ®Google Scholar
• Martinez-Castillo S, Gallego-Pinazo R, Dolz-Marco R. Adult Coats’ disease successfully managed with the dexamethasone intravitreal implant (Ozurdex) combined with retinal photocoagulation. Case Rep Ophthalmol 2012;3(1):123–127
   PubMedGoogle Scholar
• Saatci AO, Doruk HC, Yaman A. Intravitreal dexamethasone implant (ozurdex) in Coats’ disease. Case Rep Ophthalmol 2013;4(3):122–128
   PubMedGoogle Scholar
• Bazin L, Gambrelle J. Combined treatment with photodynamic therapy and intravitreal dexamethasone implant (Ozurdex) for circumscribed choroidal hemangioma. J Fr Ophthalmol 2012;35(10):798–802
   PubMed Web of Science ®Google Scholar
• Kupperman B. Safety and efficacy of dexamethasone intravitreal implant as an adjunctive therapy to Lucentis in neovascularization secondary to age-related macular degeneration, 33rd Annual Macular Society Meeting, February 24, 2010, Tucson, AZ, USA
   Google Scholar
• Heckenlively JR, Jordan BL, Aptsiauri N. Association of antiretinal antibodies and cystoid macular edema in patients with retinitis pigmentosa. American Journal of Ophthalmology 1999;127(5):565–573
   PubMed Web of Science ®Google Scholar
• Iezzi R, Guru BR, Glybina IV, et al. Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. Biomaterials 2012;33(3):979–988
   PubMed Web of Science ®Google Scholar
• Iezzi R, Kapoor KG. Ozurdex in cystoid macular edema associated with retinitis Pigmentosa, The Retina Society, October 6, 2012, Washington, DC, USA
   Google Scholar
• Srour M, Querques G, Leveziel N, et al. Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol 2013;251(6):1501–1506
   PubMed Web of Science ®Google Scholar
• Saatci AO, Selvar OB, Seymenoglu G, Yaman A. Bilateral intravitreal dexamethasone implant for retinitis pigmentosa-related macular edema. Case Rep Ophthalmol 2013;4(1):53–58
   PubMedGoogle Scholar
• Reibaldi M, Russo A, Longo A, et al. Rhegmatogenous retinal detachment with a high risk of proliferative vitreoretinopathy treated with episcleral surgery and an intravitreal dexamethasone 0.7-mg implant. Case Rep Ophthalmol 2013;4(1):79–83
   PubMedGoogle Scholar
• Shultz RW, Bakri SJ, Iezzi R. Sustained-release intravitreal dexamethasone as a surgical adjuvant in the repair of complicated retinal detachment with proliferative vitreoretinopathy, Association for Research in Vision and Ophthalmology, May 10, 2012, Fort Lauderdale, FL, USA
   Google Scholar
• Russo A, Avitabile T, Uva M, et al. Radiation macular edema after Ru-106 plaque brachytherapy for choroidal melanoma resolved by an intravitreal dexamethasone 0.7-mg implant. Case Rep Ophthalmol 2012;3(1):71–76
   PubMedGoogle Scholar
• Baillif S, Maschi C, Gastaud P, Caujolle JP. Intravitreal dexamethasone 0.7-mg implant for radiation macular edema after proton beam therapy for choroidal melanoma. Retina 2013;33(9):1784–1790
   PubMed Web of Science ®Google Scholar
• Khadem J, Khorsandzadeh S, Pan J, Pieroni C. Effects of Ozurdex on persistent macular edema after vitrectomy with membrane peeling, Association for Research in Vision and Ophthalmology, May 7, 2013, Seattle, WA, USA
   Google Scholar
• Ghosn CR, Li Y, Orilla WC, et al. Treatment of experimental anterior and intermediate uveitis by a dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011;52(6):2917–2923
   PubMed Web of Science ®Google Scholar
• Soo Hoo JR, Seibold LK, Laing AE, et al. Bleb morphology and histology in a rabbit model of glaucoma filtration surgery using Ozurdex® or mitomycin-C. Mol Vis 2012;18:714–719
   PubMed Web of Science ®Google Scholar
• Khurana RN, Appa SN, McCannel CA, et al. Dexamethasone implant anterior chamber migration: Risk factors, complications, and management strategies. Ophthalmology 2013;121(1):67--71
   Google Scholar
• Bansal R, Bansal P, Kulkarni P, et al. Wandering Ozurdex implant. J Ophthalmic Inflamm Infect 2012;2(1):1–5
   PubMedGoogle Scholar
• Kapoor KG, Shultz RW, Iezzi R. Vitreous pillow for sustained-release intravitreous drug delivery implants. Ophthalmic Surg Lasers Imaging Retina 2013;44(2):181–182
   PubMed Web of Science ®Google Scholar
• Mateo C, Alkabes M, Burés-Jelstrup A. Scleral fixation of dexamethasone intravitreal implant (Ozurdex®) in a case of angle-supported lens implantation. Int Ophthalmol 2013 Aug 9 [Epub ahead of print]
   Google Scholar
• Nascimento H, França M, García LG, et al. Subconjunctival dexamethasone implant for non-necrotizing scleritis. J Ophthalmic Inflamm Infect 2013;3(1):83--133
   Google Scholar
• Capone Jr A, Singer MA, Dodwell DG, et al. Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta Study). Retina 2013;34(2):342--351
   Google Scholar
• Coscas G, Augustin A, Bandello F, et al. Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 2013;24(1):1–9
   PubMed Web of Science ®Google Scholar